单位：[1]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China[3]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[4]Department II of breast, Linyi Cancer Hospital, Linyi, China[5]Hunan Cancer Hospital, Changsha, China[6]Department of Breast Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science &Technology, Wuhan, China华中科技大学同济医学院附属协和医院[7]Beijing Tiantan Hospital, Capital Medical University, Beijing, China首都医科大学附属天坛医院[8]The First Affiliated Hospital of Bengbu Medical College, Bengbu, China[9]The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China[10]Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China[11]Department of Breast Surgery, Shandong Provincial Cancer Hospital, Jinan, China[12]Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China[13]Department of Oncology, The First Affiliated Hospital of Xi 'an Jiaotong University, Xi 'an, China[14]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology, Wuhan, China华中科技大学同济医学院附属同济医院[15]Medical oncology，Chinese PLA General Hospital, Beijing, China[16]Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China[17]Suzhou Zanrong Pharma Limited, Shanghai, China
第一作者单位：[1]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China[3]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China[4]Department II of breast, Linyi Cancer Hospital, Linyi, China[5]Hunan Cancer Hospital, Changsha, China[6]Department of Breast Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science &Technology, Wuhan, China[7]Beijing Tiantan Hospital, Capital Medical University, Beijing, China[8]The First Affiliated Hospital of Bengbu Medical College, Bengbu, China[9]The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China[10]Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China[11]Department of Breast Surgery, Shandong Provincial Cancer Hospital, Jinan, China[12]Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China[13]Department of Oncology, The First Affiliated Hospital of Xi 'an Jiaotong University, Xi 'an, China[14]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology, Wuhan, China[15]Medical oncology，Chinese PLA General Hospital, Beijing, China[16]Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China[17]Suzhou Zanrong Pharma Limited, Shanghai, China
推荐引用方式(GB/T 7714)：
Ma Fei,Li Yiqun,Yao Herui,et al.Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Ma, Fei,Li, Yiqun,Yao, Herui,Wang, Jingfen,Ouyang, Quchang...&Zhu, Di.(2023).Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Ma, Fei,et al."Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学